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Aims Cardiovascular risk factors are used for risk stratification in primary prevention. We sought to determine if simple
cardiac risk scores are associated with magnetic resonance imaging (MRI)-detected subclinical cerebrovascular dis-
ease including carotid wall volume (CWV), carotid intraplaque haemorrhage (IPH), and silent brain infarction (SBI).
...................................................................................................................................................................................................
Methods
and results
A total of 7594 adults with no history of cardiovascular disease (CVD) underwent risk factor assessment and a
non-contrast enhanced MRI of the carotid arteries and brain using a standardized protocol in a population-based
cohort recruited between 2014 and 2018. The non-lab-based INTERHEART risk score (IHRS) was calculated in all
participants; the Framingham Risk Score was calculated in a subset who provided blood samples (n = 3889). The
association between these risk scores and MRI measures of CWV, carotid IPH, and SBI was determined. The mean
age of the cohort was 58 (8.9) years, 55% were women. Each 5-point increase (1 SD) in the IHRS was associated
with a 9 mm3 increase in CWV, adjusted for sex (P < 0.0001), a 23% increase in IPH [95% confidence interval (CI)
9–38%], and a 32% (95% CI 20–45%) increase in SBI. These associations were consistent for lacunar and
non-lacunar brain infarction. The Framingham Risk Score was also significantly associated with CWV, IPH, and SBI.
CWV was additive and independent to the risk scores in its association with IPH and SBI.
...................................................................................................................................................................................................
Conclusion Simple cardiovascular risk scores are significantly associated with the presence of MRI-detected subclinical cerebro-
vascular disease, including CWV, IPH, and SBI in an adult population without known clinical CVD.
                                                                                                                                                                                                                   
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Introduction
Cardiovascular disease (CVD) is one of the leading causes of death in
high-income countries.1 Risk factors for the two common manifesta-
tions of CVD, myocardial infarction (MI) and stroke, have been exten-
sively studied.2,3 Over 80% of the risk of these conditions is explained
by modifiable risk factors including smoking, abdominal obesity, dia-
betes, hypertension, and abnormal lipids.4 Several simple well-
validated cardiovascular scores including non-lab-based risk scores
have been proposed to evaluate the risk of developing clinical CVD.5–7
Magnetic resonance imaging (MRI) can accurately measure subclin-
ical manifestations of vascular injury and has been used to identify
individuals who have a higher risk of clinical vascular events in several
studies in different populations.8–13 MRI is superior to computed
tomography for diagnosis of silent cerebrovascular disease and does
not expose participants to radiation.11 Most prior MRI cohort studies
have been conducted in older populations,14 in which participants
were selected for MRI based on increased subclinical carotid disease
on ultrasound,14–17 and few large population-based studies have eval-
uated whether simple cardiac risk scores are associated with MRI-
detected subclinical cerebrovascular disease including carotid wall
volume (CWV), intraplaque haemorrhage (IPH), and silent brain in-
farction (SBI), subdivided by lacunar and non-lacunar types.18
In the Canadian Alliance for Healthy Hearts and Minds Cohort
Study (CAHHM), we sought to determine if simple cardiac risk scores
are associated with MRI-detected carotid artery disease and SBI.
Methods
Research ethics board approval was obtained from each participating
centre. All participants signed consent forms prior to beginning in the
study. CAHHM is a ‘cohort of cohorts’ as the majority of participants
(>80%) were recruited through existing cohorts as previously
described.19 Participants were eligible for CAHHM if they were between
ages 35 and 69 years at the time of screening, and willing to complete
questionnaires, and have physical measurements taken, and undergo an
MRI scan of the brain and carotid arteries. Participants were excluded if
they had any contraindications to undergoing an MRI scan.19 Details of
the CAHHM MRI protocol have been previously published.19 Participant
recruitment by cohort and magnet strength are provided in
Supplementary data online, Appendix S1. Participants of the First Nations
cohort also conducted in parallel are not included.20
In order to quantify the cardiovascular risk factor burden, we calcu-
lated the non-lab-based INTERHEART risk score (IHRS) using the ver-
sion that did not include data on lipid levels.6,21 The non-lab-based IHRS
is a validated score that includes data on age, sex, status with respect to
smoking, exposure to second-hand smoke, diabetes, high blood pressure,
and family history of MI, waist-to-hip ratio (WHR); home or work social
stress, depression; simple dietary questions, and physical activity. Scores
range from 0 to 48, with higher scores indicating a greater risk-factor bur-
den. Cardiovascular risk tertiles corresponding to a score of 9 or less
were classified as low risk, a score of 10 to 15 classified as medium risk,
whereas a score of 16 and higher defined higher-risk subjects.6,22 Details
concerning the development and validation of the IHRS have been pub-
lished previously.6,7 The questions and scoring system are found in
Supplementary data online, Appendix S2. In a subset of participants in
whom blood was collected (n = 3889) Apolipoprotein A1 and B were
measured which allowed calculation of the Framingham Risk Score using
age and sex-specific prediction equations; high-density lipoprotein, and
total cholesterol were estimated using measured Apolipoprotein B and
A1 values.23 Participants were scored and then categorized into sex-
specific risk categories as per the published Framingham Risk Score5
(Supplementary data online, Appendix S2).
Key MRI outcomes
The MRI protocol was previously published.19 Briefly, participants under-
went a short non-contrast enhanced scan using a 1.5 or 3 T magnet. Each
centre underwent a test scan for quality assurance which was evaluated
and validated by the two MRI core labs (brain and carotid) prior to pro-
ceeding with recruitment. Details of each MRI outcome assessment and
measurements are found in Supplementary data online, Appendix S3.
Brain
Brain infarcts identified on MRI were subcategorized based on location
and size as small (<_15 mm axial diameter) subcortical lacunes,24 which
2 S.S. Anand et al.
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..are primarily related to small vessel disease, versus larger (>15 mm axial
diameter) or cortical infarcts, which may be caused by embolism.25
Carotid arteries
Carotid artery vessel wall volume (mm3) (left, right, and combined) with-
in a 32-mm vessel length centred on each carotid bifurcation (to include
distal common and proximal internal carotid arteries) was measured by
subtracting lumen volume from total vessel volume. Carotid vessel wall
volume was defined as the maximum of the left and right carotid vessel
wall volumes and was used as a measure of atherosclerosis.13 IPH was
determined by the presence of increased signal intensity within the ca-
rotid artery wall at least one voxel in size with a signal intensity at least a
one and a half times higher than the adjacent sternocleidomastoid muscle.
Calcification or necrotic lipid cores were not assessed in the MRI
protocol.
....................................................................................................................................................................................................................
Table 1 Demographic characteristics
Overall Women Men
Number 7594 4195 3399
Age (years) 57.8 (8.9) 57.3 (8.7) 58.4 (9.1)
Non-White (%) 19.6 19.6 19.7
Urban region (%) 97.5 97.3 97.8
Family history of MI (%) 33.1 34.8 31.0
Elevated cholesterol (%) 36.7 29.8 45.2
Self-reported history of diabetes (%) 4.9 3.5 6.6
Hypertension (%) 38.4 29.9 48.8
Blood pressure (mmHg)
Systolic 129 (17) 125 (17) 134 (15)
Diastolic 79 (10) 78 (10) 82 (10)
Smoking status
Current smoker (in past year) (%) 5.4 5.2 5.6
Former smoker (quit >1 year ago) (%) 34.0 33.3 35.0
Never smoked (%) 60.6 61.5 59.4
Second hand smoke exposure (1þ h/week) (%) 4.6 4.7 4.4
Abdominal obesity (WHR) % 50.5 37.7 66.4
Leisure physical inactivity (%) 39.5 43.4 34.7
Poor diet quality (%) 16.8 13.2 21.2
Eat salty foods or snacks one or more times a day (%) 28.5 27.4 29.8
Eat deep fried foods or snacks or fast foods three or more times a week (%) 11.2 8.8 14.2
Eat less than one serving of fruit a day (%) 14.1 11.8 16.8
Eat less than one serving of vegetables a day (%) 6.4 5.0 8.2
Eat meat and/or poultry two or more times a day (%) 29.5 26.2 33.5
No alcohol intake (%) 5.8 6.8 4.5
Depression (%) 16.8 21.7 10.9
Home or work stress (%) 30.7 36.8 23.2
Married or common law (%) 75.4 69.8 82.4
Employed or retired (%) 92.7 90.1 95.9
Post-secondary education (%) 86.8 85.8 88.1
Social disadvantage scorea 1.2 (1.3) 1.3 (1.4) 1.1 (1.3)
High social disadvantage (%) 6.3 8.1 4.0
Prevalent cancer (%) 6.6 7.7 5.2
Prevalent non-atherosclerotic CVD (%) 7.0 6.6 7.4
INTERHEART risk score 10.1 (5.8) 8.8 (5.4) 11.7 (5.8)
Framingham Risk Score (N = 3889) 11.7 (4.1) 11.0 (4.1) 12.5 (3.9)
Data are presented as mean (SD) or proportions. Family history of MI indicates if either biological parent has had a MI. Elevated cholesterol is defined by self-reported high choles-
terol or those taking cholesterol-lowering statin medication daily. Self-reported diabetes is defined by those with any type of diabetes and on treatment. Hypertension is defined by
those on medication for hypertension or those with a baseline SBP >140 mmHg or DBP >90 mmHg. Abdominal obesity is defined for women as a WHR >0.85 and for men as a
WHR >0.90. Leisure physical inactivity is a self-reported measure of being mainly sedentary or doing minimal effort exercise during leisure time. Poor diet quality is defined, based on
the diet portion of the IHRS, as those with a sub-score greater than two of the possible six demerit points. Depression is self-reported as those who felt sad, blue, or depressed for
two consecutive weeks or longer, in the past year. Home or work stress is self-reported as those who had several or permanent stress at work or home in the past year.
aSocial disadvantage score was calculated by: income less than $25 000/year assigned a score of 2, income between 25 and 75 000 dollars per year a score of 1, unemployment
(including retirement) was assigned a score of 2, and living without a partner was assigned a score of 1. The maximum social disadvantage score was 5, and the lowest possible
score was 0, reflecting the least social disadvantage.
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Statistical considerations
The CAHHM cohort study has high statistical power for the testing of
associations between cardiovascular risk factors and subclinical MRI out-
comes.19 Proportions or means with standard deviations are provided
for baseline characteristics, cardiac risk scores, and baseline MRI findings.
The trend tests for MRI outcomes between low, moderate, and high-risk
categories of risk scores were made using one-way analysis of variance
with linear contrasts for continuous outcomes and the Cochran
Armitage Trend for bivariate outcomes. Overall and sex-stratified logistic
regression models were used to identify the association between a 5-
point increase in the IHRS (approximately equal to 1 SD) and each cat-
egorical MRI finding (i.e. SBI and IPH) and the continuous measure of
CWV. These analyses were then repeated in the subset of participants
with the Framingham Risk Score. Neither adjustment for centre nor so-
cial disadvantage, defined using a scoring system including employment,
income, and marital status,26 altered the results, and therefore, crude
odds ratios are presented. The addition of CWV to the risk scores associ-
ation with each of the MRI outcomes and the MRI-cerebrovascular com-
posite was performed using multivariate logistic regression.
Results
Between January 2014 and March 2018, 7594 participants free of clin-
ical cardiovascular disease completed a non-enhanced MRI scan and
had complete risk factor information collected (Supplementary data
online, Figure S1).
Demographic characteristics
The demographic characteristics of the cohort participants are found
in Table 1. Briefly, the cohort consisted of 55% women, the average age
of participants was 58 years; and 19.6% were non-white. Participants
were well educated, and social disadvantage was low (Table 1).
INTERHEARTrisk score
The mean non-lab-based IHRS was 10.1 (5.8). The frequency of com-
ponent factors of the IHRS is depicted in Table 1. The proportion of
participants who reported current smoking (5.4%) or a diagnosis of
...................................................................................................................
....................................................................................................................................................................................................................
Table 2 MRI outcomes by INTERHEARTrisk score category
INTERHEARTrisk score category
Overall Low risk Moderate risk High risk P-trenda
Number 7594 3814 2445 1335
INTERHEART risk score 10.1 (5.8) 5.5 (2.6) 12.2 (1.7) 19.4 (3.3)
Framingham Risk Score 11.7 (4.1) 9.9 (3.3) 12.6 (3.8) 15.3 (3.6)
Carotid vessel wall volume (mm3) 902.6 (167.5) 881.5 (163.1) 915.4 (166.6) 940.9 (172.9) <0.0001
Intraplaque haemorrhage 2.4% (179/7488) 1.8% (67/3783) 3.0% (72/2405) 3.1% (40/1300) 0.001
Silent brain infarction 4.0% (301/7523) 2.8% (106/3798) 4.8% (116/2413) 6.0% (79/1312) <0.0001
Lacunar 2.3% (172/7523) 1.6% (60/3798) 2.6% (62/2413) 3.8% (50/1312) <0.0001
Non-Lacunar 1.7% (129/7523) 1.2% (46/3798) 2.2% (54/2413) 2.2% (29/1312) 0.003
MRI-detected cerebrovascular disease 6.2% (462/7449) 4.5% (168/3770) 7.5% (179/2388) 8.9% (115/1291) <0.0001
Data are presented as mean (SD) or proportions (counts).
IHRS, INTERHEART risk score.
aP-trend calculate using linear contrasts for continuous data and Cochran Armitage Test for bivariate outcomes.
.................................................................................................................
....................................................................................................................................................................................................................
Table 3 MRI outcomes by Framingham Risk Score category
Framingham Risk Score category
Overall Low risk Moderate risk High risk P-trenda
Number 3889 1912 1278 699
INTERHEART risk score 10.0 (5.7) 7.1 (4.3) 11.4 (5.0) 15.4 (5.2)
Framingham Risk Score 11.7 (4.1) 8.4 (2.4) 13.4 (1.5) 17.5 (2.1)
Carotid vessel wall volume (mm3) 904.4 (167.4) 869.2 (152.9) 924.8 (170.9) 963.5 (175.9) <0.0001
Intraplaque haemorrhage 2.1% (82/3825) 1.2% (23/1891) 2.2% (27/1254) 4.7% (32/680) <0.0001
Silent brain infarction 3.6% (138/3860) 2.1% (39/1902) 3.5% (44/1264) 7.9% (55/694) <0.0001
Lacunar 2.2% (86/3860) 1.3% (24/1902) 2.1% (26/1264) 5.2% (36/694) <0.0001
Non-Lacunar 1.3% (52/3860) 0.8% (15/1902) 1.4% (18/1264) 2.7% (19/694) <0.001
MRI-detected cerebrovascular disease 5.6% (212/3814) 3.2% (61/1887) 5.5% (69/1247) 12.1% (82/680) <0.0001
Data are presented as mean (SD) or proportions (counts).
FRS, Framingham Risk Score (modified).
aP-trend calculate using linear contrasts for continuous data and Cochran Armitage Test for bivariate outcomes.
4 S.S. Anand et al.
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diabetes (4.9%) was low, whereas the proportion of participants with
hypertension (38.4%), elevated blood cholesterol including those using
a cholesterol-lowering statin (36.7%), or abdominal obesity (50.5%:
37.7% female, 66.4% male) was high. Half of the participants (3814/
7594) were classified as low risk (score of 0–9, mean 5.5), 32.2%
(2445/7594) as moderate risk (score 10–15, mean 12.2), and 17.6%
(1335/7594) were classified as high risk (score >_16, mean 19.4).
Framingham Risk Score
In the subset of the participants who provided blood samples, the
Framingham Risk Score was calculated. The mean score was 11.7 (4.1);
and 49.1% (1912/3889) of participants were classified as low risk,
32.9% (1278/3889) as intermediate, and 18.0% (699/3889) as high risk.
Association between risk scores and subclinical MRI
outcomes
The overall frequency of IPH was 2.4% (179/7488) and SBI was 4.0%
(301/7523) (lacunar: 2.3%; non-lacunar 1.7%). The proportion of par-
ticipants with subclinical cerebrovascular disease including IPH or SBI
increases progressively from low to moderate, to high risk by the
IHRS, as does the mean CWV, with a strongly significant trend statis-
tic for each outcome (Table 2). The proportion of participants with
any MRI-detected cerebrovascular disease in the low-risk strata was
4.5%, in moderate risk was 7.5%, and in high risk was 8.9%, P < 0.0001
for the IHRS categories. Similar associations were observed for the
Framingham Risk Scores (Table 3) (Figure 1A and 1B).
Each 5-point increase (about 1 SD) in the IHRS was associated
with a 23% increase in carotid IPH [95% confidence interval (CI) 9–
38%], and a 32% increase in SBI (95% CI 20–45%). A 5-point increase
in IHRS has also associated a 29% (20–39%) increase in the odds of
MRI-cerebrovascular composite of carotid IPH or SBI (Figure 2A).
The Framingham Risk Score which incorporates the lipid measures
was also significantly associated with MRI-cerebrovascular disease,
including IPH and SBI (Figure 2B). These associations were also con-
sistent by age, sex, racial-ethnic group, and social disadvantage strata
(Figure 3).
A 5-point change in IHRS and Framingham Risk Score increases
the CWV, a continuous measure of subclinical atherosclerosis, by 9
mm3 (P < 0.0001) and 11 mm3 (P = 0.0002), respectively, adjusting
for sex. We also tested if the CWV remained significantly associated
with MRI-cerebrovascular disease when added to the cardiac risk
score. Added to the IHRS, the CWV association with MRI-
cerebrovascular disease was independent and additive as was the
case for the addition of CWV to the IHRS association with SBI
(Table 4). The CWV reduces the magnitude and significance of the
IHRS association with IPH (P = 0.07). Added to the Framingham Risk
Score, CWV was independently and significantly associated with
MRI-cerebrovascular disease, for IPH and SBI (Table 5).
Discussion
We demonstrate in this large population-based cohort of adult men
and women that traditional cardiovascular risk factors as measured
by simple cardiac risk scores were associated with MRI-detected sub-
clinical cerebrovascular injury including carotid IPH and SBI (both la-
cunar and non-lacunar). These associations are consistent across the
lifespan, in both sexes, in White and non-White individuals, and low-
and high-socioeconomic groups. Furthermore, CWV, a measure of
positive remodelling and an index of atherosclerosis was independ-
ently associated with MRI-detected cerebrovascular disease, demon-
strating the potential utility of this imaging biomarker.
Assessment of subclinical vascular injury is a useful adjunct to
identify individuals who require risk factor control to prevent the
development of clinical events. Our findings add significantly to the
body of literature which shows that subclinical vascular disease
begins far earlier in life than at the time of clinical presentation of
first MI, stroke or death,27 and that pre-clinical measures of carotid
Figure 1 (A) Proportion of cohort with combined MRI-detected
cerebrovascular disease within INTERHEART risk score category
by sex. (B) Proportion of cohort with combined MRI-detected cere-
brovascular disease within Framingham Risk Score category by sex.
IHRS, INTERHEART risk score.
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Figure 2 (A) Risk of MRI-detected cerebrovascular disease per 5-point increase in the non-lab-based INTERHEART risk score. (B) Risk of MRI-
detected cerebrovascular disease per 5-point increase in the Framingham Risk Score. (A) The odds ratio and 95% confidence interval for each MRI
outcome per 5-point increase in the non-lab-based INTERHEART risk score; (B) the odds ratio and 95% confidence interval for each MRI outcome
per 5-point increase in the Framingham Risk Score. MRI-detected cerebrovascular outcome defined as intraplaque haemorrhage or silent brain
infarction.
Figure 3 Risk of combined MRI-detected cerebrovascular disease per 5-point increase in the non-lab-based INTERHEART risk score in various
sub-groups. The risk of MRI-detected CVD per 5-point increase in INTERHEART risk score is shown overall, and within selected subgroups showing
consistency of the effect by sex, age group, race, and social disadvantage category (moderate to high defined as points >/=3, low score <3).
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atherosclerosis predict the development of severe cerebrovascu-
lar injury.28
Three-dimensional MRI to determine CWV and IPH offer a direct
and precise measure of the normal and diseased wall and is superior
to carotid ultrasound because of its ability to accurately characterize
vessel wall plaque biomarkers, including plaque components, plaque
burden, and luminal stenosis.13 MRI is currently the only available clin-
ical imaging technique for the detection of plaque haemorrhage—
one marker of a vulnerable plaque in the carotid artery. Other imag-
ing biomarkers which can indicate plaque vulnerability include lipid-
rich necrotic core, calcification core,29 and calcification30 which were
not studied as part of our MRI protocol. CAHHM shows that cardiac
risk scores are significantly associated with subclinical atherosclerosis
measured by CWV and IPH. Most prior studies using MRI of the ca-
rotid arteries have been smaller in size and conducted among higher
risk individuals. The Rotterdam cohort study evaluated older individ-
uals (average age 77 years) known to have increased carotid intimal
medial thickness by ultrasound, and reported that increasing age, cig-
arette smoking, and hypertension were associated with the presence
of IPH,12,31 and that lipid measures were associated with CWV.32
Furthermore in the Rotterdam cohort increased luminal stenosis of
the carotid artery was strongly associated with IPH,32 and CAHHM
shows that a continuous measure of atherosclerosis—carotid vessel
wall volume is significantly associated with IPH.
Regarding carotid disease and clinical outcomes, IPH is associated
with an increased risk of clinical events including stroke or transient
ischaemic attack (TIA) in patients with known carotid stenosis,31,33 al-
though studies in asymptomatic individuals are very limited in size.34
The MESA study in 946 participants with increased carotid intimal
medial thickness by ultrasound, showed that an MRI-based vascular
remodelling index of the internal carotid artery was associated with
incident cardiovascular events over 5 years, and was superior to ca-
rotid intimal medial thickness as measured by ultrasound.12 Our data
in a middle-aged population without a history of CVD show that
MRI-measured CWV is significantly associated with IPH, and SBI,
over and above cardiac risk factors. Prospective follow-up of
CAHHM is ongoing in order to quantify the risk of each of these MRI
biomarkers to clinical cardiovascular outcomes and mortality.
CAHHM to our knowledge is the first report of a strong associ-
ation between multicomponent but simple cardiac risk scores and
the presence of SBI in a large population-based study. Prior cohort
studies which used MRI evaluation of SBI were smaller35 and were
conducted in older populations.17 These studies showed that increas-
ing age, hypertension, and carotid intimal thickness are risk factors for
....................................................................................................................................................................................................................
Table 4 Independent association of carotid wall volume measure of atherosclerosis in addition to INTERHEARTrisk
score on MRI cerebrovascular disease
MRI outcome N Scans Odds (95% CI) P-value
MRI-detected cerebrovascular disease 7304
IHRS (5-point increase) 1.22 (1.13–1.32) <0.0001
Carotid wall volume (100 mm3 increase) 1.30 (1.23–1.37) <0.0001
Intraplaque haemorrhage 7337
IHRS (5-point increase) 1.12 (0.99–1.27) 0.07
Carotid wall volume (100 mm3 increase) 1.54 (1.43–1.65) <0.0001
Overall silent brain infarction 7304
IHRS (5-point increase) 1.28 (1.16–1.41) <0.0001
Carotid wall volume (100 mm3 increase) 1.15 (1.07–1.22) <0.0001
....................................................................................................................................................................................................................
Table 5 Independent association of carotid wall volume measure of atherosclerosis in addition to Framingham Risk
Score on MRI cerebrovascular disease
MRI outcome N scans Odds (95% CI) P-value
MRI-detected cerebrovascular disease 3734
FRS (5-point increase) 1.78 (1.49–2.12) <0.0001
Carotid wall volume (100 mm3 increase) 1.26 (1.16–1.36) <0.0001
Intraplaque haemorrhage 3742
FRS (5-point increase) 1.47 (1.12–1.94) 0.006
Carotid wall volume (100 mm3 increase) 1.46 (1.31–1.63) <0.0001
Overall silent brain infarction 3734
FRS (5-point increase) 1.98 (1.60–2.46) <0.0001
Carotid wall volume (100 mm3 increase) 1.15 (1.04–1.27) 0.004
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SBI. In our study, a 5-point increase in the IHRS was associated with a
32% increase in the relative prevalence of SBI (95% CI 20–45%).
Furthermore, this association was consistent for lacunar and non-
lacunar infarctions, which are approximately equal in frequency in
our study. Compared to the non-lab-based IHRS, the Framingham
Risk Score was more strongly associated with SBI [odds ratio 2.02
(95% CI 1.64–2.50 per 5-point increase)] which may reflect the inclu-
sion of lipid measures, together with the other traditional cardiovas-
cular risk factors. We also show that subclinical atherosclerosis
measured by CWV was significantly associated with SBI over and
above cardiovascular risk factors. While CAHHM does not yet have
follow-up data regarding the risk of clinical stroke, prior studies indi-
cate that persons with silent brain infarcts are at three-fold increased
risk of future stroke and 1.5-fold increased risk for dementia.10,35
Our data emphasize that simple cardiac risk scores are useful to
risk stratify the population, and clinical trial strategies have directed
the use of statins and blood pressure lowering in moderate to high-
risk individuals in primary prevention.22 Recent guidelines highlight
additional risk stratification markers beyond risk scores may be
needed in cases of clinical uncertainty or patient indecision regarding
treatment, and endorse additional measures of subclinical athero-
sclerosis over the use of serum biomarkers.36 While it is impractical
to consider MRI for population-based screening, our data reaffirm
that non-invasive imaging with MRI is highly informative. In addition to
simple cardiac risk scoring, MRI-detected CWV adds additional infor-
mation regarding subclinical vascular injury of the carotid arteries and
brain.
The strengths of our analyses include CAHHM’s large sample
size, the use of standard imaging protocols and core lab readings
(Supplementary data online, Appendix S3), and the concurrent scan-
ning of multiple vascular territories. Limitations include the cross-
sectional nature of our current analysis of the cardiac risk score and
MRI-detected cerebrovascular disease, although the chance of re-
verse causation is low having used subclinical outcomes. Measures
of cognitive function have been collected and analysis is underway
to determine the relationship between subclinical cerebrovascular
disease and cognitive function. The prediction of the cardiac risk
scores and MRI-detected cerebrovascular disease on incident clin-
ical events will be reported after prospective follow-up is
completed.
Summary
Cardiovascular risk factors summarized as simple risk scores are sig-
nificantly associated with the presence of MRI-detected subclinical
cerebrovascular disease, including CWV, IPH, and SBI in an adult
population without known clinical CVD.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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